U.S. healthcare products maker Covidien Ltd expects annual sales growth of 10 to 15 percent in China over the coming years, its chief executive said on Tuesday.

The firm, which took over a local distributor in China more than a year ago, would consider more acquisitions in the country if opportunities arise, Richard Meelia told Reuters in an interview in Shanghai.

In China we would look for companies that have good technology, good manufacturing facilities, Meelia added.

He did not specify over how many years he expected the sales growth to continue.